971 0 Kommentare Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share

Transaction would add VYXEOS™, an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio

U.S. regulatory submission for VYXEOS planned by end of third quarter 2016

Jazz Pharmaceuticals to host investor conference call today, May 31, 2016 at 8:30 AM EDT (1:30 PM IST)

DUBLIN and EWING, New Jersey, May 31, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share in cash, or approximately $1.5 billion.

The transaction with Celator is well-suited to advance Jazz Pharmaceuticals' growth strategy.

VYXEOS is the first product candidate to demonstrate a statistically significant improvement in Overall Survival in patients with high-risk (secondary) AML¹
U.S. FDA Breakthrough Therapy designation granted for VYXEOS²
U.S. FDA and European Commission Orphan Drug designation for VYXEOS for the treatment of AML
VYXEOS is an innovative product candidate based on the Celator CombiPlex® platform
Anticipated long-lived exclusivity for VYXEOS
Broadens Jazz Pharmaceuticals' hematology/oncology portfolio
Worldwide development and commercialization rights to VYXEOS
Synergies with Jazz Pharmaceuticals' commercial expertise and infrastructure
Transaction expected to close in the third quarter of 2016
Transaction expected to be accretive to Non-GAAP adjusted EPS beginning in 2018 and beyond

¹ Included secondary AML and de novo AML with a karyotype characteristic of myelodysplastic syndrome (MDS)

² U.S. FDA Breakthrough Therapy designation granted for VYXEOS for the treatment of adults with therapy-related AML or AML with myelodysplasia-related changes

"Celator Pharmaceuticals is a strong strategic fit with Jazz Pharmaceuticals. VYXEOS will further diversify our product portfolio and is complementary to our clinical and commercial expertise in hematology/oncology," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "As Celator is currently preparing a regulatory submission in the U.S. for VYXEOS, this acquisition would add a new orphan product with the potential for short- and long-term revenue generation and expansion of our international commercial platform."